BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38230393)

  • 1. Retrospective cohort study for thrombocytopenia during concurrent chemoradiotherapy for rectal cancer.
    Teng Y; Ma D; Yan Y; Geng J; Liu Z; Zhu X; Li S; Zhang Y; Wang H; Cai Y; Yue H; Li Y; Wang W
    Front Oncol; 2023; 13():1289824. PubMed ID: 38230393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and dosimetric predictors of acute hematologic toxicity in rectal cancer patients undergoing chemoradiotherapy.
    Yang TJ; Oh JH; Apte A; Son CH; Deasy JO; Goodman KA
    Radiother Oncol; 2014 Oct; 113(1):29-34. PubMed ID: 25304718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective phase II study of magnetic resonance imaging guided hematopoietical bone marrow-sparing intensity-modulated radiotherapy with concurrent chemotherapy for rectal cancer.
    Jianyang W; Yuan T; Yuan T; Xin W; Ning L; Hua R; Hui F; Yanru F; Shulian W; Yongwen S; Yueping L; Weihu W; Yexiong L; Jing J
    Radiol Med; 2016 Apr; 121(4):308-14. PubMed ID: 26612321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of bone marrow irradiation dose on acute haematologic toxicity in cervical cancer patients treated with concurrent chemoradiotherapy.
    Chen M; Wang D; Bao Z; Yi Z; Mei Z; Sun S; Xiang Q; Yang C; Yang H; Qiu H; Xie C
    Radiat Oncol; 2023 Apr; 18(1):66. PubMed ID: 37031167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose to specific subregions of pelvic bone marrow defined with FDG-PET as a predictor of hematologic nadirs during concomitant chemoradiation in anal cancer patients.
    Franco P; Arcadipane F; Ragona R; Lesca A; Gallio E; Mistrangelo M; Cassoni P; Arena V; Bustreo S; Faletti R; Rondi N; Morino M; Ricardi U
    Med Oncol; 2016 Jul; 33(7):72. PubMed ID: 27277756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematologic Nadirs During Chemoradiation for Anal Cancer: Temporal Characterization and Dosimetric Predictors.
    Lee AY; Golden DW; Bazan JG; Kopec M; Pelizzari CA; Aggarwal S; Chang DT; Liauw SL
    Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):306-312. PubMed ID: 28068238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between radiation dose to ¹⁸F-FDG-PET defined active bone marrow subregions and acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy.
    Rose BS; Liang Y; Lau SK; Jensen LG; Yashar CM; Hoh CK; Mell LK
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1185-91. PubMed ID: 22270171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.
    Mell LK; Schomas DA; Salama JK; Devisetty K; Aydogan B; Miller RC; Jani AB; Kindler HL; Mundt AJ; Roeske JC; Chmura SJ
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1431-7. PubMed ID: 17996390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dosimetric predictors of acute hematologic toxicity during concurrent intensity-modulated radiotherapy and chemotherapy for anal cancer.
    Franco P; Ragona R; Arcadipane F; Mistrangelo M; Cassoni P; Rondi N; Morino M; Racca P; Ricardi U
    Clin Transl Oncol; 2017 Jan; 19(1):67-75. PubMed ID: 27037814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase II prospective nonrandomized trial of magnetic resonance imaging-guided hematopoietic bone marrow-sparing radiotherapy for gastric cancer patients with concurrent chemotherapy.
    Wang J; Tian Y; Tang Y; Wang X; Li N; Ren H; Fang H; Feng Y; Wang S; Song Y; Liu Y; Wang W; Li Y; Jin J
    Onco Targets Ther; 2016; 9():2701-7. PubMed ID: 27217780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Bone Marrow Suppression During Postoperative Chemotherapy in Rectal Cancer Patients After Preoperative Chemoradiation Therapy.
    Newman NB; Sidhu MK; Baby R; Moss RA; Nissenblatt MJ; Chen T; Lu SE; Jabbour SK
    Int J Radiat Oncol Biol Phys; 2016 Apr; 94(5):1052-60. PubMed ID: 27026312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose to Pelvic Bone Marrow Defined with FDG-PET Predicts for Hematologic Nadirs in Anal Cancer Patients Treated with Concurrent Chemo-radiation.
    Franco P; Arcadipane F; Ragona R; Lesca A; Gallio E; Mistrangelo M; Trino E; Cassoni P; Arena V; Baccega M; Racca P; Faletti R; Rondi N; Morino M; Ricardi U
    Cancer Invest; 2018; 36(5):279-288. PubMed ID: 29953269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosimetric parameters and absolute monocyte count can predict the prognosis of acute hematologic toxicity in cervical cancer patients undergoing concurrent chemotherapy and volumetric-modulated arc therapy.
    Xiang X; Ding Z; Zeng Q; Feng L; Qiu C; Chen D; Lu J; Li N
    Radiat Oncol; 2022 Mar; 17(1):48. PubMed ID: 35248087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-volume parameters of MRI-based active bone marrow predict hematologic toxicity of chemoradiotherapy for rectal cancer.
    Kuncman Ł; Stawiski K; Masłowski M; Kucharz J; Fijuth J
    Strahlenther Onkol; 2020 Nov; 196(11):998-1005. PubMed ID: 32621010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy.
    Mell LK; Kochanski JD; Roeske JC; Haslam JJ; Mehta N; Yamada SD; Hurteau JA; Collins YC; Lengyel E; Mundt AJ
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1356-65. PubMed ID: 16757127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can dosimetric parameters predict acute hematologic toxicity in rectal cancer patients treated with intensity-modulated pelvic radiotherapy?
    Wan J; Liu K; Li K; Li G; Zhang Z
    Radiat Oncol; 2015 Aug; 10():162. PubMed ID: 26238572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosimetric predictors of acute haematological toxicity in oesophageal cancer patients treated with neoadjuvant chemoradiotherapy.
    Lee J; Lin JB; Sun FJ; Lu KW; Lee CH; Chen YJ; Huang WC; Liu HC; Wu MH
    Br J Radiol; 2016 Oct; 89(1066):20160350. PubMed ID: 27556422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of chemotherapy on normal tissue complication probability models of acute hematologic toxicity in patients receiving pelvic intensity modulated radiation therapy.
    Bazan JG; Luxton G; Kozak MM; Anderson EM; Hancock SL; Kapp DS; Kidd EA; Koong AC; Chang DT
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):983-91. PubMed ID: 24161422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute hematological toxicity during post-operative bowel sparing image-guided intensity modulated radiation with concurrent cisplatin.
    Lewis S; Chopra S; Naga P; Pant S; Dandpani E; Bharadwaj N; Mahantshetty U; Engineer R; Swamidas J; Ghosh J; Gupta S; Shrivastava S
    Br J Radiol; 2018 Dec; 91(1092):20180005. PubMed ID: 30179056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of hematologic toxicity between 3DCRT and IMRT planning in cervical cancer patients after concurrent chemoradiotherapy: a national multi-center study.
    Erpolat OP; Alco G; Caglar HB; Igdem S; Saran A; Dagoglu N; Aslay I; Ozsaran Z; Demirci S; Keven E; Guney Y; Akmansu M; Kilic D; Bayman E; Etiz D; Mandel NM
    Eur J Gynaecol Oncol; 2014; 35(1):62-6. PubMed ID: 24654465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.